pegylated liposomal doxorubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   115 Trials   115 Trials   1644 News 


12345678910111213...3031»
  • ||||||||||  Talidox (doxorubicin liposomal) / Innomedica
    P1 data, PK/PD data, Journal:  Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. (Pubmed Central) -  Jun 15, 2024   
    P1
    The PK characteristics form the basis to investigate TLD-1 exposure-response (i.e., clinical efficacy) and exposure-toxicity relationships in the future. Once such relationships have been established, the developed population PK model can be further used in model-informed precision dosing strategies.
  • ||||||||||  CDX-1140 / Celldex, Mobista (CDX-301) / Celldex
    Enrollment change, Combination therapy, Metastases:  CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov) -  Jun 13, 2024   
    P1,  N=30, Recruiting, 
    Once such relationships have been established, the developed population PK model can be further used in model-informed precision dosing strategies. N=45 --> 30
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
    Review, Journal, BRCA Biomarker, PARP Biomarker:  Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? (Pubmed Central) -  Jun 12, 2024   
    The main results of clinical trials and studies involving trabectedin/PLD, along with hints of Breast Cancer genes (BRCA)-mutated and BRCAness phenotype cases, are critically discussed. Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond.
  • ||||||||||  SL-172154 / Shattuck
    Enrollment closed:  Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov) -  May 30, 2024   
    P1,  N=86, Active, not recruiting, 
    Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond. Enrolling by invitation --> Active, not recruiting
  • ||||||||||  peposertib (M3814) / EMD Serono
    Preclinical, Journal:  Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. (Pubmed Central) -  May 25, 2024   
    We established a well-tolerated preclinical treatment regimen combining peposertib with pegylated liposomal doxorubicin (PLD) and demonstrated strong anti-tumor efficacy in cell-line-derived and patient-derived TNBC xenograft models in vivo. Taken together, our findings provide evidence that co-treatment with peposertib has the potential to enhance the efficacy of anthracycline/TOPO II-based chemotherapies, and it provides a promising strategy to improve treatment outcomes for TNBC patients.
  • ||||||||||  azenosertib (ZN-c3) / Zentalis Pharma
    Phase classification, Trial completion date, Trial primary completion date, Combination therapy:  ZN-c3-002: A Study of ZN-c3 in Patients With Ovarian Cancer (clinicaltrials.gov) -  May 24, 2024   
    P1,  N=140, Recruiting, 
    Taken together, our findings provide evidence that co-treatment with peposertib has the potential to enhance the efficacy of anthracycline/TOPO II-based chemotherapies, and it provides a promising strategy to improve treatment outcomes for TNBC patients. Phase classification: P1b --> P1 | Trial completion date: Aug 2024 --> Feb 2027 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  Journal:  Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2?. (Pubmed Central) -  Apr 27, 2024   
    Based on the previous studies on the doxorubicin (DOX) formulation for cancer targeting therapy, we developed a novel DOX delivery formulation for the targeting chemotherapy of HCC and DOX resistant HCC...Based on the above, an HCC targeting and MDR inhibiting DOX delivery liposomal formulation, HCSP4/Lipo-DOX/miR125a-5p was synthesized and tested for its HCC therapeutic efficacy in vitro...The potential therapeutic mechanism of the DOX delivery formulation was explored, and the formulation inhibited the expression of MDR-relevant genes including ATP-binding cassette subfamily B member 1 (ABCB1, also known as P-glycoprotein), ATP-binding cassette subfamily C member 5 (ABCC5), enhancer of zeste homolog 2 (EZH2), and ATPase Na+/K+ transporting subunit beta 1 (ATP1B1). Our study presents a novel targeting chemotherapeutic drug formulation for the therapy of HCC, especially for drug resistant HCC, although it is primarily and needs further study in vivo, but provided a new strategy for the development of novel anticancer drugs.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Journal:  EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer. (Pubmed Central) -  Apr 25, 2024   
    Herein, we investigated the targeting of PEGylated liposomal doxorubicin (Caelyx), a powerful off-the-shelf antitumoral liposomal drug, to EGFR as a therapeutic strategy to improve the specific delivery and intratumoral accumulation of chemotherapy in NSCLC...The approach demonstrated increased penetration within 3D spheroids and was effective at targeting and suppressing the growth of NSCLC tumors in vivo while reducing drug delivery to the heart. EGFR targeting represents a successful approach to enhance the selectivity and therapeutic potency of liposomal chemotherapy toward NSCLC.
  • ||||||||||  disulfiram / Generic mfg.
    Trial completion date, Trial primary completion date:  Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (clinicaltrials.gov) -  Apr 24, 2024   
    P1,  N=24, Recruiting, 
    EGFR targeting represents a successful approach to enhance the selectivity and therapeutic potency of liposomal chemotherapy toward NSCLC. Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Oct 2024
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Enrollment open, Trial primary completion date, Combination therapy:  Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov) -  Apr 24, 2024   
    P1/2,  N=72, Recruiting, 
    Patients aged 18 to 70 years old with previously untreated stage II Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2025 --> Nov 2026
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Novel PLGA-based nanoformulation decreases doxorubicin-induced cardiotoxicity. (Pubmed Central) -  Apr 23, 2024   
    In the case of LipoDOX, autophagy and apoptosis were still detectable, whereas PLGADOX induced only detectable mitochondrial toxicity. Cardiotoxic effects were frequently sex-related with the greater risk of cardiotoxicity observed mostly in male rats.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Review, Journal:  Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications. (Pubmed Central) -  Apr 13, 2024   
    Although several liposomal formulations are in the clinic (e.g., DOXIL) for cancer therapy, there are many challenges associated with traditional liposomes...In this review, the authors provide an overview of the evolution of lipidic nanocarriers, spanning from conventional liposomes to solid lipid nanoparticles, with a special emphasis on the development and application of cubosomes. Additionally, it delves into recent applications and preclinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians.
  • ||||||||||  Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
    Trial completion date, Trial primary completion date, Surgery:  Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov) -  Apr 8, 2024   
    P1,  N=40, Active, not recruiting, 
    Additionally, it delves into recent applications and preclinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  maplirpacept (TTI-622) / Pfizer
    Trial termination, Combination therapy:  Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) -  Apr 4, 2024   
    P1/2,  N=10, Terminated, 
    Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Journal:  Ion Quantitation in Liposomal Products Using RP-HPLC with Charged Aerosol Detection. (Pubmed Central) -  Mar 24, 2024   
    In this protocol, we focused on the quantitation of ammonium and sulfate ions in liposomal products, using generic PEGylated liposomal doxorubicin as an example. This method can be extended to calcium, acetate, and other ions in different liposomal formulations with slight modifications.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Biomarker, Journal, Tumor microenvironment:  A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas. (Pubmed Central) -  Mar 23, 2024   
    In conclusion, our research underscores the unique and synergistic potential of combining mechanotherapeutics and sonopermeation. Both approaches are undergoing clinical trials to enhance cancer therapy and have the potential to significantly improve nano-immunotherapy in sarcomas.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin. (Pubmed Central) -  Mar 17, 2024   
    The study suggests that PLD-based NAC may provide substantial benefits in terms of DFS and OS, along with a safe cardiac toxicity profile, in patients with stage II-III breast cancer. An advanced computer model analyzed the brain delivery of two distinct formulations, Doxil
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study (Section 20) -  Mar 5, 2024 - Abstract #AACR2024AACR_7601;    
    DNA/DOX nanocomplexes are amenable to rigorous chemistry, manufacturing, and controls (CMC) evaluation with proven anti-cancer efficacy and improved safety profiles. Clinical trials on DNA/DOX nanocomplexes for cancer chemotherapy are warranted to fully validate their clinical utilities.